Alpelisib

An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in… (More)

Topic mentions per year

Topic mentions per year

2015-2017
02420152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
  • Cancer discovery
  • 2018
The PI3Kα inhibitor alpelisib achieved a 58.2% disease control rate in PIK3CA-altered solid tumors. 
Is this relevant?
2018
2018
Purpose We report the first-in-human phase Ia study to our knowledge ( ClinicalTrials.gov identifier: NCT01219699) identifying… (More)
Is this relevant?
2017
2017
PURPOSE Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110α, has shown synergistic antitumor… (More)
Is this relevant?
2017
2017
Tamoxifen is the standard first-line hormonal therapy for premenopausal women with estrogen receptor (ER)-positive metastatic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to sustained suppression of MAPK signaling and… (More)
Is this relevant?
2017
2017
The human mass balance study is the definitive study for the assessment of absorption, distribution, metabolism, and excretion… (More)
Is this relevant?
2015
2015
To determine the pharmacokinetics of the p110α-selective inhibitor alpelisib (BYL719) in humans, to identify metabolites in… (More)
Is this relevant?